Carterra

Carterra

バイオテクノロジー

Salt Lake City、UT5,887人のフォロワー

High-throughput discovery and characterization technology

概要

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com.

業種
バイオテクノロジー
会社規模
社員 51 - 200名
本社
Salt Lake City、UT
種類
非上場企業
創立
2005
専門分野
biotechnology、antibody discovery、label-free、epitope binning、kinetic characterization、SPR、epitope mapping、cancer、neuroscience、infectious disease、immunooncology、antibody development、B-Cell Enrichment、phage display、protein-protein、hybridoma 、B Cell Cloning 、covid19、immunity monitoring 、vaccine research 、serology 、hybridoma screening

場所

Carterraの社員

アップデート

類似するページ

資金調達

Carterra 合計8ラウンド

最終ラウンド

Series 不明

$8,090,487.00

投資家およびグループ

PerkinElmer +1 その他の投資家
Crunchbaseで詳しい情報を表示